WHO resumes coronavirus trial on malaria drug hydroxychloroquine

Geneva: The World Health Organisation (WHO) on Wednesday announced that based on the latest data review, the clinical trial of malaria drug hydroxychloroquine on COVID-19 patients will continue.

WHO Director-General Tedros Adhanom Ghebreyesus said that experts have been reviewing the data and recommended that “there are no reasons to modify the trial protocol.”

“The Executive Group received this recommendation and endorsed continuation of all arms of the Solidarity Trial, including hydroxychloroquine.”

The Solidarity Trial is a WHO-sponsored plan to evaluate the safety and efficacy of four drugs and drug combinations against COVID-19, which include hydroxychloroquine.